《大行報告》花旗升康方生物(09926.HK)目標價至64元 關注次季AK112-303數據
花旗發表報告指,康方生物(09926.HK)2023財年收入為45億元人民幣,按年增長440%,其中包括cadonilimab銷售額13.58億元人民幣、其他產品銷售額2.46億元人民幣和29億元人民幣的預付款。淨利潤為19.4億元人民幣,2022財年淨虧損14.2億元人民幣。
該行將康方生物2024和2025財年收入預測分別上調10%和6%,以反映最新的銷售趨勢。因此每股盈利預測從0.69和-0.2元分別調整至-0.63和0.09元人民幣,並看好即將於次季公布的AK112-303數據和商業化前景。目標價由56元升至64元,維持評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.